efimosfermin

Business news, market intelligence, and global industry analysis.

The Latest

Haleon plc invests £65M in Shanghai oral health plant as China becomes central to its global growth strategy

Haleon (NYSE, LSE: HLN) bets on China’s oral health boom with £65m Shanghai manufacturing facility

Could subcutaneous PD-1 therapy reshape oncology treatment logistics in China?

Cargo theft is rising across North America. Can Eagle Vision Security’s iFM platform stop it before it starts?

The hidden problem with GLP-1 weight loss and Veru Inc.’s bet to fix it (NASDAQ: VERU)

GSK Delivers Strong Q1 2025 as Specialty Medicines and Pipeline Momentum Drive Profits

GSK to acquire efimosfermin from Boston Pharmaceuticals for $2bn to bolster liver disease pipeline

GSK acquires Phase III-ready efimosfermin from Boston Pharmaceuticals for $2B, expanding its liver disease pipeline with a fibrosis-reversing specialty drug.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

May 14, 2025